Psilocybin Therapy for Depression in Parkinson’s Disease (PDP2)

This randomised controlled trial (n=60) will assess the efficacy of oral psilocybin therapy for depression in individuals with Parkinson’s disease.

Conducted by Joshua Woolley, MD, PhD, at the University of California, San Francisco, the study aims to determine if psilocybin can alleviate depressive symptoms in people with early to moderate stage Parkinson’s disease. Participants, aged 40 to 80, who experience moderate or greater depression and meet all criteria, will receive two doses of psilocybin (ranging from 1 to 25 mg) administered in a medically monitored setting.

The trial includes a series of preparation and integration psychotherapy sessions, clinical assessments, neuroimaging, non-invasive brain stimulation, and blood draws. The primary endpoints are to evaluate changes in depression, safety, and tolerability, with follow-up extending to three months after the second session.

Topic Depression Neurocognitive Disorders
Compound Psilocybin
Country United States of America
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

University of California San Francisco
At UCSF, there are two research teams dedicated to the study of psychedelics; the Neuroscape Psychedelic Division and the Translational Psychedelic Research Program.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.